SGLT2 Inhibitors and Treatment of Heart Failure in Severe Renal Insufficiency

Summary

In the treatment of heart failure (HF), SGLT-2 inhibitor (SGLT-2i) can significantly improve the clinical outcome and quality of life related to HF. The current data show that SGLT-2i is effective and safe in improving HF outcomes in patients with chronic kidney disease (CKD) stage 4, but there is little clinical evidence in patients with eGFR\<20 ml/min/1.73 m2. Therefore, our research is designed to confirm that SGLT-2i can improve the outcome of HF in patients with chronic heart failure with reduced ejection fraction (HFrEF) and severe chronic renal insufficiency (eGFR\<20ml/min/1.73m2).

Timeline

Start

2023-03-09

Primary completion

2024-04-16

Completion

2024-04-16

Outcome

Outcome not reported

Stopped: “Double blind packaged drug is up to expiration date”

Drugs

Indications